Christophidis N, Dawborn J K, Vajda F J
Med J Aust. 1978 May 6;1(9):512-4. doi: 10.5694/j.1326-5377.1978.tb112591.x.
The pharmacokinetics of cefoxitin, a new cephamycin antibiotic, were studied in six patients who were undergoing total hip replacement, and who were given cefoxitin to provide prophylactic cover at the time of operation. Later, the efficacy of cefoxitin was studied in nine patients with severe acute infections. The mean elimination phase half-life of cefoxitin which was obtained in this study (83 to 87 minutes) was significantly longer than that obtained in other studies. Cefoxitin was also found to be effective in lung and urinary tract infections against sensitive organisms. It was well tolerated, and the only side effect was that of phlebitis in long-term therapy. Cefoxitin may be valuable for prophylactic use in bowel and orthopaedic surgery.
头孢西丁是一种新型头孢霉素类抗生素，对6例接受全髋关节置换术的患者的药代动力学进行了研究，这些患者在手术时给予头孢西丁以提供预防性覆盖。后来，对9例严重急性感染患者的头孢西丁疗效进行了研究。本研究中获得的头孢西丁平均消除相半衰期（83至87分钟）明显长于其他研究。还发现头孢西丁对肺部和泌尿系统感染中的敏感菌有效。其耐受性良好，唯一的副作用是长期治疗中的静脉炎。头孢西丁在肠道和矫形外科手术的预防性使用中可能有价值。
